Hansen's disease and COVID-19 co-infection in Brazil

Taynah Alves Rocha Repsold; Simon M. Collin; Raquel Carvalho Bouth; Selma Regina Penha Silva Cerqueira; Marisa Simon Brezinscki; Rebeca Ruppert Galarda Baptista Peixoto; Andrea Maia Fernandes de Araújo Fonseca; Marlene Leandro dos Santos Peixoto; Seyna Rabelo Mendes; Ciro Martins Gomes; Claudio Guedes Salgado; Patrícia D. Deps

doi:10.1111/ijd.16319

Hansen's disease and COVID-19 co-infection in Brazil

Taynah Alves Rocha Repsold, Simon M. Collin, Raquel Carvalho Bouth, Selma Regina Penha Silva Cerqueira, Marisa Simon Brezinscki, Rebeca Ruppert Galarda Baptista Peixoto, Andrea Maia Fernandes de Araújo Fonseca, Marlene Leandro dos Santos Peixoto, Seyna Rabelo Mendes, Ciro Martins Gomes, Claudio Guedes Salgado, Patrícia D. Deps^*

^*Corresponding author for this work

UK Health Security Agency

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Background: The implications of COVID-19 co-infection in patients under treatment for Hansen's disease (HD, leprosy) remain uncertain. We aimed to describe clinical characteristics, treatments, and outcomes in patients with HD and COVID-19 in Brazil.

Methods: Cross-sectional study recruiting adult HD patients with PCR-confirmed COVID-19 from five HD treatment centers in Brazil between March 1, 2020, and March 31, 2021. At the time of this study, no patient had received COVID-19 vaccine.

Results: Of 1377 patients under treatment for HD, 70 (5.1%) were diagnosed with COVID-19. Of these, 41 (58.6%) had PCR-confirmed COVID-19, comprising 19 men and 22 women, aged 24–67 (median 45) years. HD was multibacillary in 39/41 patients. Eight patients ceased WHO Multi-Drug Therapy for HD, three for lack of drugs, two because of COVID-19, and three for other reasons. Of the 33 who continued treatment, 26 were on the standard regimen and seven an alternative regimen. Seventeen patients were receiving oral prednisone, including nine patients with type 1 reaction, four with type 2 reaction, three with neuritis, and one with rheumatologic disease. Twelve patients were hospitalized for COVID-19, and six patients died, of whom three had hypertension and one also had type 2 diabetes and obesity.

Conclusions: COVID-19 and Hansen's disease co-infection did not appear to change the clinical picture of either disease in this cross-sectional study. The wider impact of the pandemic on persons affected by HD requires follow-up and monitoring.

Original language	English
Pages (from-to)	1506-1510
Number of pages	5
Journal	International Journal of Dermatology
Volume	61
Issue number	12
Early online date	1 Jul 2022
DOIs	https://doi.org/10.1111/ijd.16319
Publication status	Published - Dec 2022

Bibliographical note

Funding Information: This study received no specific funding. CGS had support from VALE S.A. (grant no. 27756/2019).

Open Access: No Open Access licence.

Publisher Copyright: © 2022 the International Society of Dermatology.

Citation: Repsold, T.A.R., Collin, S.M., Bouth, R.C., Cerqueira, S.R.P.S., Brezinscki, M.S., Peixoto, R.R.G.B., Fonseca, A.M.F.d.A., Peixoto, M.L.d.S., Rabelo Mendes, S., Gomes, C.M., Salgado, C.G. and Deps, P.D. (2022), Hansen's disease and COVID-19 co-infection in Brazil. Int J Dermatol, 61: 1506-1510. https://doi.org/10.1111/ijd.16319

DOI: https://doi.org/10.1111/ijd.16319

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/ijd.16319

Cite this

Repsold, T. A. R., Collin, S. M., Bouth, R. C., Cerqueira, S. R. P. S., Brezinscki, M. S., Peixoto, R. R. G. B., Fonseca, A. M. F. D. A., Peixoto, M. L. D. S., Rabelo Mendes, S., Gomes, C. M., Salgado, C. G., & Deps, P. D. (2022). Hansen's disease and COVID-19 co-infection in Brazil. International Journal of Dermatology, 61(12), 1506-1510. https://doi.org/10.1111/ijd.16319

@article{abdd6be5a8094413a53a2b3489eb10d9,

title = "Hansen's disease and COVID-19 co-infection in Brazil",

abstract = "Background: The implications of COVID-19 co-infection in patients under treatment for Hansen's disease (HD, leprosy) remain uncertain. We aimed to describe clinical characteristics, treatments, and outcomes in patients with HD and COVID-19 in Brazil. Methods: Cross-sectional study recruiting adult HD patients with PCR-confirmed COVID-19 from five HD treatment centers in Brazil between March 1, 2020, and March 31, 2021. At the time of this study, no patient had received COVID-19 vaccine. Results: Of 1377 patients under treatment for HD, 70 (5.1%) were diagnosed with COVID-19. Of these, 41 (58.6%) had PCR-confirmed COVID-19, comprising 19 men and 22 women, aged 24–67 (median 45) years. HD was multibacillary in 39/41 patients. Eight patients ceased WHO Multi-Drug Therapy for HD, three for lack of drugs, two because of COVID-19, and three for other reasons. Of the 33 who continued treatment, 26 were on the standard regimen and seven an alternative regimen. Seventeen patients were receiving oral prednisone, including nine patients with type 1 reaction, four with type 2 reaction, three with neuritis, and one with rheumatologic disease. Twelve patients were hospitalized for COVID-19, and six patients died, of whom three had hypertension and one also had type 2 diabetes and obesity. Conclusions: COVID-19 and Hansen's disease co-infection did not appear to change the clinical picture of either disease in this cross-sectional study. The wider impact of the pandemic on persons affected by HD requires follow-up and monitoring.",

author = "Repsold, {Taynah Alves Rocha} and Collin, {Simon M.} and Bouth, {Raquel Carvalho} and Cerqueira, {Selma Regina Penha Silva} and Brezinscki, {Marisa Simon} and Peixoto, {Rebeca Ruppert Galarda Baptista} and Fonseca, {Andrea Maia Fernandes de Ara{\'u}jo} and Peixoto, {Marlene Leandro dos Santos} and {Rabelo Mendes}, Seyna and Gomes, {Ciro Martins} and Salgado, {Claudio Guedes} and Deps, {Patr{\'i}cia D.}",

note = "Funding Information: This study received no specific funding. CGS had support from VALE S.A. (grant no. 27756/2019). Open Access: No Open Access licence. Publisher Copyright: {\textcopyright} 2022 the International Society of Dermatology. Citation: Repsold, T.A.R., Collin, S.M., Bouth, R.C., Cerqueira, S.R.P.S., Brezinscki, M.S., Peixoto, R.R.G.B., Fonseca, A.M.F.d.A., Peixoto, M.L.d.S., Rabelo Mendes, S., Gomes, C.M., Salgado, C.G. and Deps, P.D. (2022), Hansen's disease and COVID-19 co-infection in Brazil. Int J Dermatol, 61: 1506-1510. https://doi.org/10.1111/ijd.16319 DOI: https://doi.org/10.1111/ijd.16319",

year = "2022",

month = dec,

doi = "10.1111/ijd.16319",

language = "English",

volume = "61",

pages = "1506--1510",

journal = "International Journal of Dermatology",

issn = "0011-9059",

publisher = "wiley",

number = "12",

}

TY - JOUR

T1 - Hansen's disease and COVID-19 co-infection in Brazil

AU - Repsold, Taynah Alves Rocha

AU - Collin, Simon M.

AU - Bouth, Raquel Carvalho

AU - Cerqueira, Selma Regina Penha Silva

AU - Brezinscki, Marisa Simon

AU - Peixoto, Rebeca Ruppert Galarda Baptista

AU - Fonseca, Andrea Maia Fernandes de Araújo

AU - Peixoto, Marlene Leandro dos Santos

AU - Rabelo Mendes, Seyna

AU - Gomes, Ciro Martins

AU - Salgado, Claudio Guedes

AU - Deps, Patrícia D.

N1 - Funding Information: This study received no specific funding. CGS had support from VALE S.A. (grant no. 27756/2019). Open Access: No Open Access licence. Publisher Copyright: © 2022 the International Society of Dermatology. Citation: Repsold, T.A.R., Collin, S.M., Bouth, R.C., Cerqueira, S.R.P.S., Brezinscki, M.S., Peixoto, R.R.G.B., Fonseca, A.M.F.d.A., Peixoto, M.L.d.S., Rabelo Mendes, S., Gomes, C.M., Salgado, C.G. and Deps, P.D. (2022), Hansen's disease and COVID-19 co-infection in Brazil. Int J Dermatol, 61: 1506-1510. https://doi.org/10.1111/ijd.16319 DOI: https://doi.org/10.1111/ijd.16319

PY - 2022/12

Y1 - 2022/12

N2 - Background: The implications of COVID-19 co-infection in patients under treatment for Hansen's disease (HD, leprosy) remain uncertain. We aimed to describe clinical characteristics, treatments, and outcomes in patients with HD and COVID-19 in Brazil. Methods: Cross-sectional study recruiting adult HD patients with PCR-confirmed COVID-19 from five HD treatment centers in Brazil between March 1, 2020, and March 31, 2021. At the time of this study, no patient had received COVID-19 vaccine. Results: Of 1377 patients under treatment for HD, 70 (5.1%) were diagnosed with COVID-19. Of these, 41 (58.6%) had PCR-confirmed COVID-19, comprising 19 men and 22 women, aged 24–67 (median 45) years. HD was multibacillary in 39/41 patients. Eight patients ceased WHO Multi-Drug Therapy for HD, three for lack of drugs, two because of COVID-19, and three for other reasons. Of the 33 who continued treatment, 26 were on the standard regimen and seven an alternative regimen. Seventeen patients were receiving oral prednisone, including nine patients with type 1 reaction, four with type 2 reaction, three with neuritis, and one with rheumatologic disease. Twelve patients were hospitalized for COVID-19, and six patients died, of whom three had hypertension and one also had type 2 diabetes and obesity. Conclusions: COVID-19 and Hansen's disease co-infection did not appear to change the clinical picture of either disease in this cross-sectional study. The wider impact of the pandemic on persons affected by HD requires follow-up and monitoring.

AB - Background: The implications of COVID-19 co-infection in patients under treatment for Hansen's disease (HD, leprosy) remain uncertain. We aimed to describe clinical characteristics, treatments, and outcomes in patients with HD and COVID-19 in Brazil. Methods: Cross-sectional study recruiting adult HD patients with PCR-confirmed COVID-19 from five HD treatment centers in Brazil between March 1, 2020, and March 31, 2021. At the time of this study, no patient had received COVID-19 vaccine. Results: Of 1377 patients under treatment for HD, 70 (5.1%) were diagnosed with COVID-19. Of these, 41 (58.6%) had PCR-confirmed COVID-19, comprising 19 men and 22 women, aged 24–67 (median 45) years. HD was multibacillary in 39/41 patients. Eight patients ceased WHO Multi-Drug Therapy for HD, three for lack of drugs, two because of COVID-19, and three for other reasons. Of the 33 who continued treatment, 26 were on the standard regimen and seven an alternative regimen. Seventeen patients were receiving oral prednisone, including nine patients with type 1 reaction, four with type 2 reaction, three with neuritis, and one with rheumatologic disease. Twelve patients were hospitalized for COVID-19, and six patients died, of whom three had hypertension and one also had type 2 diabetes and obesity. Conclusions: COVID-19 and Hansen's disease co-infection did not appear to change the clinical picture of either disease in this cross-sectional study. The wider impact of the pandemic on persons affected by HD requires follow-up and monitoring.

UR - http://www.scopus.com/inward/record.url?scp=85133178938&partnerID=8YFLogxK

U2 - 10.1111/ijd.16319

DO - 10.1111/ijd.16319

M3 - Article

AN - SCOPUS:85133178938

SN - 0011-9059

VL - 61

SP - 1506

EP - 1510

JO - International Journal of Dermatology

JF - International Journal of Dermatology

IS - 12

ER -

Hansen's disease and COVID-19 co-infection in Brazil

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this